An Approved Vaccine To Treat Prostate Cancer Has Few Side Effects

An Approved Vaccine To Treat Prostate Cancer Has Few Side Effects.
The newly approved medical prostate cancer vaccine, Provenge, is innocuous and has few position effects, a new study finds. In April, the US Food and Drug Administration approved the vaccine for use in men with advanced prostate cancer who had failed hormone therapy. "Provenge was approved based on both safeness and clinical data," said head researcher Dr Simon J Hall, chairman of urology at Mount Sinai Medical Center in New York City.

This sanctuary data shows that there are very limited side effects. The gain of the vaccine for patients with metastatic hormone-resistant prostate cancer is that it has fewer side slang shit than chemotherapy, which is the only other treatment option for these patients. In addition, Provenge has improved survival over chemotherapy.

The ordinary survival time for men given Provenge is 4,5 months, although some patients saw their lives extended by two to three years. "This is a newly close by treatment, with very limited surface effects, compared to anything else that a man would be considering in this state". Hall was to present the results on Monday at the American Urological Association annual assignation in San Francisco.

Data from four phase 3 trials, which included 904 men randomized to either Provenge or placebo, showed the vaccine extended survival, improved supremacy of freshness and had only mild side effects. In fact, more than 83 percent of the men who received Provenge were able to do appear as activities without any restrictions, the researchers noted.

A New Therapeutic Vaccine Against Prostate Cancer

A New Therapeutic Vaccine Against Prostate Cancer.
A newly approved beneficial prostate cancer vaccine won the abide Wednesday of a Medicare admonition committee, increasing the chances that Medicare will pay for the drug. Officials from Medicare, the federal guaranty program for the elderly and disabled, will consider the committee's vote when making a final decision on payment. Such a determination is expected in several months, the Wall Street Journal reported. The vaccine, called Provenge and made by the Dendreon Corp, costs $93000 per tireless and extends survival by about four months on average, according to results from clinical trials.

A office published in July in the New England Journal of Medicine found that the vaccine extended the lives of men with metastatic tumors wilful to bar hormonal treatment, compared with no treatment. And the therapy involved less toxicity than chemotherapy.

Provenge is a salutary (not preventive) vaccine made from the patient's own white blood cells. Once removed from the patient, the cells are treated with the panacea and placed back into the patient. These treated cells then trigger an invulnerable response that in turn kills cancer cells, leaving average cells unharmed.

The vaccine is given intravenously in a three-dose schedule delivered in two-week intervals. "The plan of trying to harness the immune system to fight cancer has been something that occupy have tried to attain for many years; this is one such strategy," study lead researcher Dr Philip Kantoff, a professor of remedy at Harvard Medical School and a medical oncologist at the Dana-Farber Cancer Institute in Boston, told HealthDay.